INTRODUCTION {#s1}
============

There is growing recognition of an important role for de novo variants in specific syndromes ([@GRIFFINMCS001735C4]; [@GRIFFINMCS001735C12]), as well as in more complex phenotypes like autism ([@GRIFFINMCS001735C24]), intellectual disability ([@GRIFFINMCS001735C9]), and epilepsy ([@GRIFFINMCS001735C11]). Because these variants were detected in DNA from leukocytes of patients with a neurological disorder, it is presumed that these variants were newly acquired in parental gametes and present constitutionally in the zygote. However, disease-causing de novo somatic variants may arise postzygotically and be present only in a fraction of the cells in the brain. In fact, somatic variants have previously been reported in conditions associated with medically intractable epilepsy, including hypothalamic hamartoma ([@GRIFFINMCS001735C13]), focal cortical dysplasia ([@GRIFFINMCS001735C20]; [@GRIFFINMCS001735C23]), and hemimegalencephaly (HME) (HP:0007206), a severe malformation of cortical development characterized by enlargement of one cerebral hemisphere ([@GRIFFINMCS001735C18]; [@GRIFFINMCS001735C26]; [@GRIFFINMCS001735C10]). The mammalian target of rapamycin (mTOR) cascade has been implicated in a number of malformations of cortical development including HME ([@GRIFFINMCS001735C8]). Consistent with the known involvement of the mTOR-signaling pathway in HME, all identified somatic variants detected in surgically resected brain tissue occur in genes comprising the phosphoinositide 3-kinase (PI3K)--protein kinase B (AKT)--mTOR pathway and collectively are estimated to explain ∼30% of the cases of HME ([@GRIFFINMCS001735C18]; [@GRIFFINMCS001735C26]; [@GRIFFINMCS001735C10]). Previous studies have shown clearly that the mTOR cascade is activated in many cases of HME as evidenced by phosphoactivation of mTOR substrates such as p70S6kinase and ribosomal S6 protein ([@GRIFFINMCS001735C21]; [@GRIFFINMCS001735C1]; [@GRIFFINMCS001735C5]). Most cases of HME are sporadic, with only one report of familial HME ([@GRIFFINMCS001735C19]), suggesting that new variants likely play an important role in the genetic architecture of this disease.

In this study, we sought to identify somatic variants in HME by genetically analyzing paired DNA samples from unaffected cells (leukocytes) and abnormal brain tissue from two patients to identify brain tissue--specific variants.

RESULTS {#s2}
=======

Clinical Presentation {#s2a}
---------------------

HME1 is a female of European ancestry. She was developmentally delayed as an infant, and her first seizure (HP:0001250) occurred at 22 mo. Magnetic resonance imaging (MRI) at that time showed generalized overgrowth of the left frontotemporal lobes with regional cortical thickening and shallow sulci consistent with left-sided HME ([Fig. 1](#GRIFFINMCS001735F1){ref-type="fig"}A). Her seizures became progressively worse between 2 and 3 yr, occurring up to 50 times per day. At 36 mo, HME1 underwent left frontotemporoparietal craniotomy and functional hemispherectomy. Postoperatively, she made developmental gains and was seizure-free for nearly 24 mo. Seizures recurred 24 mo posthemispherectomy. MRI revealed residual fibers crossing the corpus callosum, and electroencephalography (EEG) was supportive of seizures secondarily generalizing from the left hemisphere. The patient then underwent a left-sided anatomic hemispherectomy with completion of the corpus callostomy 26 mo after her first surgery. Postoperatively, the patient has been free of overt seizures for 20 mo. However, EEG still shows brief bursts of spikes in the right hemisphere without clinical correlate. Neuropathologic analysis of a portion of the resected tissue revealed disorganized cerebral cortical cytoarchitecture with balloon cells ([Fig. 1](#GRIFFINMCS001735F1){ref-type="fig"}B) and persistent radial glial ladders (not shown). She was seen at 8 yr, and the examination showed that she was speaking in short sentences but with relatively severe dysarthria. She could read at the second-grade level. She also presented with right central facial and right upper extremity hemiplegia of the hand and hemiparesis of the arm and leg with the ability to walk and right-sided hyperreflexia and an upgoing toe on the right. She also had a right homonymous hemianopsia.

![Clinical and neuropathologic findings in HME1 and HME2. (*A*) T2-weighted magnetic resonance image (MRI) of HME1 showing left-sided hemimegalencephaly (HME). (*B*) Hematoxylin and eosin (H&E) staining of cortical brain tissue slices showing balloon cells (black arrows) in HME1 (left, 10× and right, 60×). (*C*) T2-weighted MRI of HME2 showing left-sided HME with pachygyria in the left parietooccipital region. (*D*) H&E (40×) or NeuN (60×) staining of cortical brain tissue slices from HME2 showing balloon cells (black arrow).](GriffinMCS001735_F1){#GRIFFINMCS001735F1}

HME2 is a female of European ancestry. After an uncomplicated birth, HME2 began having complex partial seizures at 3 wk and drug-resistant infantile spasms shortly thereafter. MRI showed left HME with a broad area of parietooccipital pachygyria ([Fig. 1](#GRIFFINMCS001735F1){ref-type="fig"}C). She had a functional hemispherectomy at 6 mo. Postoperatively, subject continued to have seizures, and MRI showed some remaining connection at the corpus callosum and temporal lobe. At 6 mo after the initial surgery, the patient underwent completion of the functional hemispherectomy. The patient is currently seizure-free, 36 mo after the second surgery. Neuropathologic analysis of a portion of the resected tissue revealed markedly disorganized cerebral cortical cytoarchitecture with balloon cells ([Fig. 1](#GRIFFINMCS001735F1){ref-type="fig"}D). When seen at 5 yr, she was able to write her name with assistance. She knew three out of three colors and pointed to objects in the room but could not give definitions of other objects. She was able to count to 20. She was able to take up to 26 steps but needed someone to be behind her to make sure she did not fall. She presented with a right homonymous hemianopsia. She had right central facial and right upper extremity hemiplegia of the hand and hemiparesis of the arm and leg, as well as right-sided hyperreflexia and an upgoing toe on the right.

Genomic Analyses {#s2b}
----------------

The somatic variant calling pipeline from the paired exome sequence data of HME1 identified six candidate somatic variants predicted to be functional (possibly damaging or probably damaging by PolyPhen-2 missense, splice, or stop-gained single-nucleotide variants or frameshift indels) and absent from public exome databases and in-house sequenced controls ([Supplemental Table 1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001735/-/DC1)). One of these candidate variants was a missense somatic single-nucleotide variant (sSNV) in *MTOR* (NM_004958.3:c.4447T\>C;p.Cys1483Arg). Given the previous report of somatic variants in *MTOR* and genes comprising the PI3K--AKT--mTOR pathway in HME ([@GRIFFINMCS001735C18]; [@GRIFFINMCS001735C10]), we confirmed the presence and absence of the candidate somatic variant in *MTOR* in the brain and blood, respectively ([Table 1](#GRIFFINMCS001735TB1){ref-type="table"}). Both the sequencing data and the digital droplet polymerase chain reaction (PCR) analyses support that the variant is present in ∼6% of alleles in the brain ([Fig. 2](#GRIFFINMCS001735F2){ref-type="fig"}). We also confirmed that the variant was not detectable in DNA from the buccal swab from HME1, indicating the somatic variant occurred after the formation of the neuroectoderm.

![Genetic findings in HME1. (*A*) Aligned next-generation sequencing reads at the mammalian target of rapamycin (MTOR) variant marked by vertical gray lines (NM_004958.3:c.4447T\>C;p.Cys1483Arg) with 5/85 (6%) supporting the variant allele in brain tissue DNA, compared with 0/57 (0%) in blood. The figure was generated using the Integrated Genomics Viewer. (*B*) Quantitative digital droplet polymerase chain reaction (PCR) of DNA from the brain, blood, and buccal scraping of HME1, compared with DNA from brain tissue and leukocytes of controls, indicating that the variant allele frequency (VAF%) in the brain tissue is ∼6%. Limit of detection of the assay is indicated by the dashed red line.](GriffinMCS001735_F2){#GRIFFINMCS001735F2}

###### 

Somatic variants identified in the brain tissue of two patients with hemimegalencephaly

  Patient   Gene       Chr.   HGVS DNA reference       HGVS protein reference   Variant type                              Predicted effect                                 dbSNP/dbVar ID
  --------- ---------- ------ ------------------------ ------------------------ ----------------------------------------- ------------------------------------------------ ----------------
  HME1      *MTOR*     1      NM_004958.3:c.4447T\>C   p.Cys1483Arg             Substitution                              SIFT: deleterious; PolyPhen: probably damaging   N/A
  HME2      *ZNF597*   16     N/A                      N/A                      Maternal uniparental disomy of Chr. 16p   Hypomethylation of *ZNF597*                      N/A

HGVS, Human Genome Variation Society; dbSNP, Database for Short Genetic Variations; dbVar, Database of Genomic Structural Variation.

Using genome-wide genotyping of DNA from affected brain and blood for HME2, we identified somatic uniparental disomy (UPD) of the p-arm of Chromosome 16, as evidenced by an allelic imbalance of heterozygous variants along 16p in only the DNA from the abnormal brain tissue, despite no difference in the intensity of the overall genotyping signal (logRratio) ([Fig. 3](#GRIFFINMCS001735F3){ref-type="fig"}A; [Table 1](#GRIFFINMCS001735TB1){ref-type="table"}). A similar pattern was seen in DNA extracted for abnormal hippocampal tissue ([Supplemental Fig. 1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001735/-/DC1)). Fluorescence in situ hybridization (FISH) confirmed the presence of a normal diploid Chromosome 16 ([Supplemental Fig. 2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001735/-/DC1)) in temporal cortical brain tissue, confirming that the allelic imbalance was not due to duplication of 16p in some cells of the affected tissue. Similar to the somatic variant in HME1, we did not detect UPD in leukocyte DNA ([Fig. 3](#GRIFFINMCS001735F3){ref-type="fig"}A) or buccal DNA ([Supplemental Fig. 1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001735/-/DC1)). Consistent with the maternal allele being overrepresented in the abnormal brain tissue, the ratio of the intensity of the genotyping probe measuring the alternate allele to the total intensity (b-allele frequency) for heterozygous variants in the brain tissue DNA of HME2 that are absent in the mother (i.e., those that were inherited from the father) is reduced compared with the blood. The opposite is true for heterozygous variants in HME2 brain absent in the father; that is, there is a greater representation of alleles that were inherited from the mother in the brain compared with the blood ([Fig. 3](#GRIFFINMCS001735F3){ref-type="fig"}B).

![Genetic findings in HME2. (*A*) Genome-wide genotyping data revealing somatic uniparental disomy (UPD) of the p-arm of Chromosome 16, as evidenced by an allelic imbalance exclusively in brain tissue based on the B-allele frequency for heterozygous variants deviating from 0.5 in DNA from brain tissue (red dots) compared DNA from leukocytes (blue dots), without changes in the overall signal intensity (logRratio). (*B*) Bar graph of the B-allele frequency of heterozygous variants detected in the leukocytes of probands broken out by the parental genotype.](GriffinMCS001735_F3){#GRIFFINMCS001735F3}

Exome sequencing was performed with both brain and blood for HME2 to further scan for candidate disease-causing somatic variants. No somatic variants were identified from the paired exome sequence data that were predicted to be functional (possibly damaging or probably damaging by PolyPhen-2 missense, splice, or stop-gained SNVs or frameshift indels) and absent from public exome databases and in-house sequenced controls. The 16p UPD event was confirmed in the exome-sequencing data for the brain tissue as a somatic loss of heterozygosity by comparing the allele frequencies of the sequencing reads for the brain and leukocyte DNA. To ensure that no variants were overlooked because of a small percentage of the cells from the affected tissue, we performed targeted capture and sequencing of genes in the PI3K--AKT--mTOR pathway; the targeted regions were sequenced at an average sequencing coverage greater than 600-fold in both the brain and leukocyte DNA ([Table 2](#GRIFFINMCS001735TB2){ref-type="table"}). No candidate somatic variants were detected with in-depth analysis of 192 genes in the pathway, including *DEPDC5*, *PIK3CA*, *MTOR*, or *AKT3*.

###### 

Sequencing statistics for whole-exome sequencing and targeted resequencing (TRS)

  Family   Sequencing type   Individual   Tissue   Total reads   Percent of mapped reads   Average fold coverage across targeted regions   Percent of targeted region at 20× coverage
  -------- ----------------- ------------ -------- ------------- ------------------------- ----------------------------------------------- --------------------------------------------
  HME1     Exome             Proband      Brain    221,970,984   99.3                      173                                             90.2
  HME1     Exome             Proband      Blood    146,470,259   99.3                      114                                             85.1
  HME2     Exome             Proband      Brain    194,995,169   99.2                      116                                             94.3
  HME2     Exome             Proband      Blood    244,128,539   99.3                      140                                             95.4
  HME2     TRS               Proband      Brain    12,546,960    91.3                      679                                             99.4
  HME2     TRS               Proband      Blood    17,601,695    92.8                      975                                             99.5
  HME2     Exome             Mother       Blood    150,325,726   99.2                      106                                             94.1
  HME2     Exome             Father       Blood    206,747,009   99.3                      137                                             95.3

Because the number of copies of 16p genes is intact, UPD would be benign unless there is an imprinted gene or if a maternally inherited heterozygous variant was a deleterious homozygous variant in the subset of affected cells. To explore the latter hypothesis, we performed exome sequencing on leukocyte DNA from HME2 and from both unaffected parents. More than 94% of bases comprising the Consensus Coding DNA Sequence (CCDS) genes on the p-arm of Chromosome 16 were sequenced to at least 10-fold; one rare missense variant in *PMM2* was transmitted to HME2 from the mother where the homozygous genotype at this site was not found in the unaffected parents or the databases of controls. However, this variant is predicted to be benign by PolyPhen-2 and therefore not a convincing candidate. We also used the exome data to look for rare de novo or newly homozygous variants that might be responsible for HME, and none were detected in the protein-coding regions of the genome in HME2.

We next compared the methylation profiles of temporal cortex tissue of HME2 with those of control brains, which included both autopsy brains and fresh frozen tissue from patients with focal cortical dysplasia documented not to have somatic UPD on the p-arm of Chromosome 16, to look for genomically imprinted loci along 16p. Statistical analyses comparing the methylation level of candidate hemimethylated sites in control tissue with that of HME2 identified two candidate imprinted loci, spanning *ZNF597* and *UMOD* (multiplicity adjusted *P-*values of 0.012 and 0.032, respectively). *ZNF597* has been previously reported to be imprinted ([@GRIFFINMCS001735C22]; [@GRIFFINMCS001735C3]).

Functional Analyses {#s2c}
-------------------

To confirm imprinting of *ZNF597* in HME2, we evaluated allelic expression of inherited heterozygous variants in the brain tissue of the proband from the RNA-seq data. We confirmed that *ZNF597* is imprinted in the brain based on preferential mRNA expression of the maternal allele at a heterozygous polymorphism inherited from the mother (rs12737, HME2-leukocyte genotype: heterozygous (variant allele frequency in the sequencing reads \[VAF\] = 56%); HME2-brain genotype: heterozygous \[VAF = 72%\], HME2-mRNA genotype: homozygous \[VAF = 98%\]; maternal genotype: homozygous \[VAF = 100%\]; paternal genotype: heterozygous \[VAF = 55%\]). We also directly show that the UPD variant in the brain is associated with increased *ZNF597* mRNA expression and protein expression in HME2 compared with control and HME1 levels, consistent with hypomethylation in HME2 ([Fig. 4](#GRIFFINMCS001735F4){ref-type="fig"}). *UMOD* was not expressed in the brain tissue, suggesting that this additional signal was a false positive. We directly show the UPD variant in the brain is associated with increased *ZNF597* mRNA expression and protein expression, consistent with hypomethylation ([Fig. 4](#GRIFFINMCS001735F4){ref-type="fig"}). We observed no evidence of methylation differences in the six PI3K--AKT--mTOR pathway genes on 16p ([Supplemental Fig. 3](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001735/-/DC1)).

![Increased (*A*) mRNA and (*B*) protein expression of *ZNF597* in HME2 specimen lysates compared with HME1 and control brain tissue.](GriffinMCS001735_F4){#GRIFFINMCS001735F4}

mTOR Hyperactivation {#s2d}
--------------------

Because all previously identified somatic variants in HME have implicated the PI3K--AKT--mTOR pathway, we first assessed the level of mTOR expression in brain tissue from the two patients. Like the previously reported HME-associated somatic *MTOR* variants ([@GRIFFINMCS001735C18]), immunolabeling with phospho-S6 antibodies reveals evidence for up-regulated mTOR signaling in HME1 brain tissue ([Fig. 5](#GRIFFINMCS001735F5){ref-type="fig"}). Similar to HME1, up-regulation of mTOR signaling was observed in brain tissue from HME2 ([Fig. 5](#GRIFFINMCS001735F5){ref-type="fig"}).

![mTOR activation in resected hemimegalencephaly (HME) tissues. (*A*) Phospho-S6 immunohistochemistry shows a few cytomegalic neurons and balloon cells in HME1. The *inset* shows a dysmorphic neuron and a balloon cell. (*B*) Phospho-S6 immunohistochemistry shows numerous cytomegalic neurons in HME2. Scale bar, 100 µm.](GriffinMCS001735_F5){#GRIFFINMCS001735F5}

ZNF597 Expression {#s2e}
-----------------

Because little is known about *ZNF597* expression in normal human brain, we investigated the anatomic expression of *ZNF597* in control brain specimens. There was modest expression of *ZNF597* in control cortex and cerebellum ([Supplemental Fig. 4](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001735/-/DC1)). ZNF597 was detected in human fibroblasts, astrocytes, and U87 glioma cells ([Supplemental Fig. 4](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001735/-/DC1)). To better define interacting proteins, we used coimmunoprecipitation to define potential protein-binding partners of ZNF597. Previous work suggested an interaction between ZNF597 and ZDHHC17 (zinc finger, DHHC-type Containing 17), also known as Huntingtin Interacting Protein 14 (HIP14), which is a palmotyl acetyl transferase, known to interact with huntingtin, in yeast ([@GRIFFINMCS001735C6]). We found that ZNF597 binds to ZDHHC17 ([Fig. 6](#GRIFFINMCS001735F6){ref-type="fig"}) when it is overexpressed in both 293T and U87 glioma cell lines.

![ZNF597 interacts with ZDHHC17. (*A*) Basal expression of ZNF597 and ZDHHC17 in several cell lines---for example, U87 glioma cells, SY5Y cells, 293FT cells, and human melanoma WM3734 cells. Note absent expression of ZDHHC17 in HTB186 cells. (*B*) (*Top*) Western assay demonstrates detection of ZDHHC17 protein following elution of bead-captured, Flag-tagged ZNF597 expressed in HTB186 cells (ZDHHC17 is not expressed by these cells under basal conditions). (*Bottom*) Detection of ZNF597 protein following elution of magnetic-bead-captured, Flag-tagged ZDHHC17 expressed in HTB186 cells. Some of the ZNF597 may be endogenous protein in HTB186 cells. *Middle* lanes depict minimal elution of bound proteins with either phosphate-buffered saline (PBS) or radio-immunoprecipitation assay (RIPA) buffer washes.](GriffinMCS001735_F6){#GRIFFINMCS001735F6}

DISCUSSION {#s3}
==========

We identified and confirmed somatic variants in both patients evaluated in this study. In the first patient (HME1), we identified a somatic variant in *MTOR* (c.4447T\>C;p.Cys1483Arg), located 1 bp away from the previously reported somatic HME variant (c.4448T\>C; p.Cys1483Tyr) ([@GRIFFINMCS001735C10]). A previous study identified the Cys1483Arg somatic variant in an individual with focal cortical dysplasia type IIb in 6% of alleles in the brain ([@GRIFFINMCS001735C20]). In HME2, we found novel somatic UPD of the p-arm of Chromosome 16. UPD of the p-arm of Chromosome 16 of maternal origin in the germline is associated with abnormal intrauterine growth and a range of congenital malformations ([@GRIFFINMCS001735C15]). Maternal UPD of Chromosome 16 has not been, to date, associated with malformations of cortical development ([@GRIFFINMCS001735C17]); however, one case of germline maternal UPD 16 has been reported in an individual with likely Silver--Russell syndrome and relative macrocephaly ([@GRIFFINMCS001735C2]; [@GRIFFINMCS001735C28]). In this study, we show that the 16p UPD leads to hypomethylation and subsequent overexpression of *ZNF597*. A previous study also reported that maternal UPD of Chromosome 16 results in hypomethylation of *ZNF597* ([@GRIFFINMCS001735C22])*.* While overexpression of *ZNF597* is one plausible explanation for the disease, we cannot rule out a maternally inherited heterozygous variant in a noncoding region that could be a deleterious homozygous variant in the cells with UPD or the presence of a noncoding de novo variant on the paternal chromosome that might be rescued by the somatic UPD event ([@GRIFFINMCS001735C14]).

To date, somatic mutations identified in HME are thought to lead to the malformation of cortical development by altering mTOR signaling cascade ([@GRIFFINMCS001735C18]; [@GRIFFINMCS001735C26]). Consistent with that observation, up-regulated mTOR signaling was found in the brain tissue of HME1 harboring a somatic *MTOR* mutation ([Fig. 5](#GRIFFINMCS001735F5){ref-type="fig"}). Interestingly, we also show evidence for up-regulated mTOR-signaling in HME2, despite the role of *ZNF597* to the PI3K--AKT--mTOR pathway or in brain development more generally is not yet fully characterized. A previous study identified ZNF597 as a differentially spliced isoform of HIT-4 in mouse ([@GRIFFINMCS001735C29]). Both HIT-4 and ZNF597 are zinc finger proteins that contain C2H2 domains, although their functions as putative transcription factors have not been confirmed. HIT-4/ZNF597 mRNA is widely expressed in rodent brain, and knockout of HIT-4/ZNF597 is lethal at embryonic day 7.5. Because the function of ZNF597 is unknown, we confirmed a previous finding that ZNF597 can bind to ZDHHC17, a Huntington interacting protein, thus providing some early insights into potential cell signaling pathways. Future studies are needed to determine whether hypomethylation of ZNF597 as a result of UPD of 16p can alter mTOR signaling and to more fully define the function of ZNF597 in cell growth and proliferation.

METHODS {#s4}
=======

Study Subjects {#s4a}
--------------

Two patients with HME were enrolled into the Genetics of Epilepsy study at Duke University. A blood sample was collected from the probands with HME and the unaffected parents. A buccal swab was also obtained from the probands. Both patients underwent resective surgery for the treatment of refractory seizures. Brain tissue specimens were collected and flash frozen from the temporal cortex of the first patient (HME1) and from the hippocampus and temporal cortex of the second patient (HME2). Formalin-fixed paraffin-embedded specimens were also collected as part of routine pathological analysis. Phenotypic information was compiled by interviewing the family, consulting with the treating neurologists and neurosurgeons, and by collecting data from the medical records.

The control brain tissue consisted of autopsy collected temporal cortex tissue obtained from the Kathleen Price Bryan Brain Bank or the Brain and Tissue Bank for Developmental Disorders (University of Maryland), as well as freshly collected brain tissue specimens from patients with focal cortical dysplasia. Control DNA samples from leukocytes were obtained from healthy controls enrolled in the Genetics of Memory Study at Duke University. All controls were confirmed not to have Chromosome 16p UPD or the *MTOR* variant identified in HME1.

All sample and phenotypic data collection were performed in accordance with the ethical standards set forth by the Duke University Institutional Review Board or the Maryland University Institutional Review Board and Committee on Human Research.

Genome-Wide Genotyping, Exome Sequencing, Targeted Resequencing, and RNA-seq {#s4b}
----------------------------------------------------------------------------

DNA samples extracted from leukocytes and brain tissue specimens collected from the HME probands were genotyped on the Illumina Human 610-Quad genome-wide genotyping array using standard protocols. DNA from buccal scrapings was genotyped on the Illumina HumanCore-12 genome-wide genotyping array. Copy-number variants were inferred using PennCNVsoftware ([@GRIFFINMCS001735C32]). Exome sequencing and RNA-seq were performed within the Genomic Analysis Facility in the Center for Human Genome Variation (CHGV) at Duke University. Targeted resequencing was performed within the High Throughput Sequencing Facility in the Institute for Genomic Medicine (IGM) at Columbia University. For exome sequencing, sequencing libraries were prepared using the Illumina TruSeq or Kapa library preparation kit following the manufacturer\'s protocol, and targeted capture of the exome was performed with either Illumina TruSeq or Roche SeqCap EZ Exome v3.0 exome enrichment kits according to the manufacturer\'s protocol. For targeted resequencing, sequencing libraries were prepared using the Illumina TruSeq library preparation kit following the manufacturer\'s protocol, and targeted capture of the genes within the PI3K--AKT--mTOR pathway was performed with a custom designed enrichment kit (Roche SeqCap EZ) targeting 192 genes in the pathway, including the known HME genes (*MTOR*, *AKT3*, *PIK3CA*, and *DEPDC5*). Paired-end sequencing reads that were 125 bp in length were generated on either an Illumina HiSeq 2000 or an Illumina HiSeq 2500. Samples were exome-sequenced to an average coverage greater than 100-fold, and at least 95% of the CCDS genes were sequenced to at least 10-fold coverage on an Illumina HiSeq 2000 or 2500 sequencer. For RNA-seq, the Illumina TruSeq RNA kit was used to create sequencing libraries. Alignment and variant calling methods for exome-sequenced samples were described previously ([@GRIFFINMCS001735C11]). Alignment of RNA-seq sequencing fragments was performed using TopHat software ([@GRIFFINMCS001735C31]).

The minor allele frequency of identified variants on the p-arm of Chromosome 16 was assessed in internally available controls nonenriched for neuropsychiatric diseases and sequenced as part of other genetics studies (*n* = 2005), in approximately 6500 samples represented in the Exome Variant Server, National Heart, Lung, and Blood Institute (NHLBI) Exome Sequencing Project (ESP), Seattle, WA (<http://evs.gs.washington.edu/EVS> \[August 2012\]), and in approximately 65,000 samples present in the Exome Aggregation Consortium server (ExAC), Broad Institute, Cambridge, MA (<http://exac.broadinstitute.org>). sSNVs and somatic indels were called using Mutect2 ([@GRIFFINMCS001735C7]) and Varscan-2 software ([@GRIFFINMCS001735C16]); loss of heterozygosity variants were called using Varscan-2. Qualifying variants were designated as those variants predicted to be deleterious (possibly damaging or probably damaging by PolyPhen-2 missense, splice, or stop-gained SNVs or frameshift indels) and missing from public databases and in-house controls, as well as from control brains that had been previously sequenced. Visual inspection of the alignment of the sequencing reads was performed with the Integrative Genomics Viewer ([@GRIFFINMCS001735C27]; [@GRIFFINMCS001735C30]) to ensure the quality of the sequencing alignments and to rule out any variants with strand bias (i.e., variants for which the alternate allele only appeared on the plus or minus strand, which is indicative of a sequencing error).

Confirmation of Somatic MTOR Variant {#s4c}
------------------------------------

The presence and absence of the *MTOR* variant in brain and blood/buccal DNA, respectively, was confirmed using digital droplet PCR (Bio-Rad QX200 Droplet Digital PCR System) beginning from 45 ng of DNA and using a standard digital droplet PCR protocol for a custom-designed TaqMan probe--based assay (F:CCATCATTCTAGGAAGCTCACCATT, R:CGACCCAGAGCTGATGCT, FAM-ATGCGCCGCCTCG, VIC-CATGCGCTGCCTCG).

Fluorescence In Situ Hybridization {#s4d}
----------------------------------

Interphase fluorescence in situ hybridization (FISH) analysis was performed using the dual-color "break-apart" probe specific for the CBFB locus from Abbott Molecular. This probe set can detect rearrangement of the CBFB locus at 16q22, either by inversion 16 or translocation 16;16. In this context, it was used as a control for enumeration of the long arm (q) of Chromosome 16. FISH analysis was also performed using clone RP11-19H6 (BlueGnome) as a probe for enumeration of the short arm (p) of Chromosome 16. Localization of the probe to 16p13.3 was confirmed by inverted- DAPI banding.

Genome-Wide Methylation {#s4e}
-----------------------

Genome-wide methylation data were generated using the Infinium HumanMethylation450 BeadChip Kit. Unnormalized intensity data were normalized using wateRmelon methylation analysis package. Normalized data are shown in [Supplemental Figure 5A](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001735/-/DC1). The distribution of the normalized intensity signal across 25 well-established imprinted regions ([@GRIFFINMCS001735C25]) in control brain tissue samples is shown in [Supplemental Figure 5B](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001735/-/DC1). Ninety percent of these known hemimethylated sites were located between normalized intensity values of 0.35 and 0.77. We then identified additional candidate imprinted sites along the p-arm of Chromosome 16 by filtering the average normalized intensity signals in control brain tissue also within this range. A total of 2635 probes along the 16p were within this range and annotated to a gene (446 genes). At each of these 2635 candidate imprinted loci, we calculated the sum of the squared *t*-statistic across each of the 446 genes, comparing the methylation signals for the two replicate analyses of DNA from the temporal cortex of HME2 with that for the DNA from 19 control temporal cortex specimens. We then calculated a marginal *P*-value for each gene by permutating the case and control status 10,000 times and comparing the observed sum of squared *t*-statistics to its permutation distribution. We also calculated multiplicity adjusted (for the 446 genes tested) *P*-values by comparing the sum of squared *t*-statistic for each gene with the permutation distribution of the max sum of squared *t*-statistics over all 446 genes.

ZNF597 Expression {#s4f}
-----------------

*ZNF597* mRNA expression was assessed using a commercially available TaqMan-based assay (*ZNF597*: Hs00331334_m1, Life Technologies). Quantitative real-time PCR was performed on RNA that was reverse-transcribed into cDNA by use of a High Capacity cDNA Synthesis Kit (Life Technologies). *ZNF597* expression levels were normalized to mRNA expression of *GAPDH* (Life Technologies).

ZNF597 protein expression was assessed by western assay. Briefly, protein lysates were generated from HME1, HME2, and a single control cortex specimen using RIPA lysis buffer (50 mM Tris--HCl (pH 8.0); 150 mM NaCl; 1% NP-40; 0.5% sodium deoxycholate, 0.1% SDS, protease and phosphatase inhibitors). Protein (30 µg) was separated on 4%--15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) Tris--Glycine gel (Bio-Rad), transferred onto polyvinylidene fluoride (PVDF) membranes, which were probed with ZNF antibodies overnight at 4°C and horseradish peroxidase (HRP)-conjugated secondary antibodies (GE Healthcare) for 1 h at room temperature (RT), and then visualized with ECL or ECL Plus (GE Healthcare). Membranes were probed with antibodies to GAPDH (Cell Signaling) to ensure equal protein loading. Additionally, cell lysates were taken from human fibroblasts (Coriel), human astrocytes (courtesy D. Kolson), and U87 glioma cells (courtesy D. O\'Rorke) for analysis of ZNF597 expression.

Immunohistochemistry Assessing mTOR Signaling {#s4g}
---------------------------------------------

Formalin-fixed, paraffin-embedded HME1 and HME2 brain specimens were microtome-sectioned at 7 µm and individually probed with antibodies recognizing the phosphorylated isoform of ribosomal S6 protein (phospho-S6; Ser 235/236; Cell Signaling, rabbit polyclonal, 1:200), native S6 protein (Cell Signaling, rabbit polyclonal, 1:200), or ZNF597 (AbCam, rabbit polyclonal, 1:200) overnight at 4°C. Sections were then probed with biotinylated secondary antibodies for 1 h at RT and visualized using avidin--biotin conjugation (Vectastain ABC Elite; Vector Labs) with 3,3′-diaminobenzidine. Dehydrated sections were mounted with coverslips (Permount). Light-microscopy images were acquired using a Leica DM4000 B microscope.

ZNF597 Protein--Protein Interactions {#s4h}
------------------------------------

*ZNF597* cDNA was obtained from OriGene (\#RC206744) and cloned into pLD-puro-CcVA vector for high expression. The VA tag attached to the carboxyl terminus of ZNF597 consists of three Flag epitopes, a double tobacco etch virus (TEV) protease cleavage site, six His, and a StrepIII tag in series, ∼12 kDa in mass. ZDHHC17 (HIP14) cDNA was obtained from OriGene (\#RC207982L1) containing both Myc and Flag tags at the carboxyl terminus. ZNF597 was expressed in 293FT cells, and ZDHHC17 was expressed in HTB186 cells (cerebellar medulloblastoma cells \[ATCC\]). Protein lysates were prepared with PBS-T (0.1% Tween-20) containing protease and phosphatase inhibitors. Anti-Flag Magnetic Beads (Sigma-Aldrich, A2220) were used for coimmunoprecipitation to trap ZNF597-Flag or ZDHHC17-Flag. The mixture was incubated at 4°C with end-to-end rotation overnight. Beads were washed with PBS and then RIPA buffer, and then were boiled in SDS-PAGE loading buffer. The released proteins were resolved on 4%--12% Bis--Tris protein gel (Invitrogen) and probed with corresponding antibody.

ADDITIONAL INFORMATION {#s5}
======================

Data Deposition and Access {#s5a}
--------------------------

The variants discovered in this study are listed in ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar>) under accession numbers SCV000485071 (NM_004958.3:c.4447T\>C) and SCV000485072 (uniparental disomy of Chromosome 16p). Patient consent was not obtained to deposit raw sequencing data.
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